



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Eptifibatide Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Article 61(3) /	- Notification acc. Article 61(3) -	02/05/2025		PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/N/0000267275	Update of the package leaflet to introduce a list of local representatives.				
Variation type II / EMA/VR/0000244821	This was an application for a group of variations. B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.d The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes - Accepted B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.d The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes - Accepted	20/03/2025	N/A		
Variation type IA_IN / EMA/VR/0000254111	This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including	24/02/2025	N/A	Annex II and PL	

	batch control/testing - Accepted				
Variation type IB / EMA/VR/0000244815	B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted	06/02/2025	N/A		
Variation type IA / EMA/VR/0000233760	A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted	14/11/2024	N/A		